A Descending Cranial Nerve Palsy During the Christmas Holidays

Lang B Vincent A . Autoimmune disorders of the neuromuscular junction. Curr Opin Pharmacol. 2009;9(3):336-340.

Evoli A Tonali PA Padua L . Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain. 2003;126(10):2304-2311.

Hoch W McConville J Helms S Newsom-Davis J Melms A Vincent A . Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365-368.

McConville J Farrugia ME Beeson D . Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55(4):580-584.

Scuderi F Marino M Colonna L . Anti-P110 autoantibodies identify a subtype of “seronegative” myasthenia gravis with prominent oculobulbar involvement. Lab Invest. 2002;82(9):1139-1146.

Lambert Eh Elmqvist D . Quantal components of end-plate potentials in the myasthenic syndrome. Ann N Y Acad Sci. 1971;183:183-199.

Newsom-Davis J Murray N Wray D . Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor. Muscle Nerve. 1982;5(9S):S17-S20.

Andrews PI . Autoimmune myasthenia gravis in childhood. Semin Neurol. 2004;24(1):101-110.

Engel AG Sine SM . Current understanding of congenital myasthenic syndromes. Curr Opin Pharmacol. 2005;5(3):308-321.

Engel AG Lambert EH Mulder DM . A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol. 1982;11(6):553-569.

Weissman BA Raveh L . Therapy against organophosphate poisoning: the importance of anticholinergic drugs with antiglutamatergic properties. Toxicol Appl Pharmacol. 2008;232(2):351-358.

Tattersall J . Seizure activity post organophosphate exposure. Front Biosci. 2009;14:3688-3711.

Van Doorn PA Ruts L Jacobs BC . Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome Lancet Neurol. 2008;7(10):939-950.

Lo YL . Clinical and immunological spectrum of the Miller Fisher syndrome. Muscle Nerve. 2007;36(5):615-627.

Kincaid O Lipton HL . Viral myelitis: an update. Curr Neurol Neurosci Rep. 2006;6(6):469-474.

Ooi MH Wong SC Lewthwaite P Cardosa MJ Solomon T . Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9(11):1097-1105.

Sejvar JJ Haddad MB Tierney BC . Neurologic manifestations and outcome of West Nile virus infection. JAMA. 2003;290(4):511-515.

Davis LE DeBiasi R Goade DE . West Nile virus neuroinvasive disease. Ann Neurol. 2006;60(3):286-300.

Hernández-Albújar S Arribas JR Royo A González-García JJ Peña JM Vázquez JJ . Tuberculous radiculomyelitis complicating tuberculous meningitis: case report and review. Clin Infect Dis. 2000;30(6):915-921.

Centers for Disease Control and Prevention (1998) Botulism in the United States, 1899–1996. In: Handbook for Epidemiologists, Clinicians, and Laboratory Workers. CDC, Atlanta, GA: CDC; 1998:15-22.

Fenicia L Anniballi F Aureli P . Intestinal toxemia botulism in Italy, 1984-2005. Eur J Clin Microbiol Infect Dis. 2007;26(6):385-394.

Tseng-Ong L Mitchell W.G . Infant botulism: 20 years’ experience at a single institution. J Child Neurol. 2007;22(12);1333-1337.

Fenicia L Anniballi F . Infant botulism. Annali dell’ Istituto superiore di sanitá 2009, 45, 134–146.

Underwood K Rubin S Deakers T . Infant botulism: A 30 year experience spanning the introduction of botulism immune globulin intravenous in the intensive care unit at Childrens Hospital Los Angeles. Pediatrics. 2007;120(6):e1380-e1385.

Fenicia L Franciosa G Pourshaban M Aureli P . Intestinal toxemia botulism in two young people, caused by Clostridium butyricum type E. Clin Infect Dis. 1999;29(6):1381-1387.

Lindstrom M Korkeala H . Laboratory diagnostics of botulism. Clin Microbiol Rev. 2006;19(2):298-314.

Sato Y Kimata N Miyahara S Nihei H Agishi T Takahashi M . Extracorporeal adsorption as a new approach to treatment of botulism. ASAIO J. 2000;46(6):783-785.